---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-003253"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-10-26T23:59:59+00:00"
generated_at: "2026-06-28T17:59:14.636899+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Chemomab shareholders approve CEO Dale Pfost employment terms at special meeting

## Summary
- Special meeting held Oct 25, 2021; 42.74% of outstanding shares represented.
- Proposal to approve CEO Dr. Dale Pfost's employment terms passed with 96.3M for, 1.2M against.
- Pfost was engaged as CEO on September 1, 2021.
- Vote satisfied requisite majority under Israeli Companies Law.

## SEC filing metadata
- accession: 0001178913-21-003253
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003253/0001178913-21-003253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321003253/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-003253
- JSON: https://secwatch.observer/filing/0001178913-21-003253.json
- Plain text: https://secwatch.observer/filing/0001178913-21-003253.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.